首页> 外文期刊>BMC Complementary and Alternative Medicine >Bioactive fractions and compound of Ardisia crispa roots exhibit anti-arthritic properties mediated via angiogenesis inhibition in vitro
【24h】

Bioactive fractions and compound of Ardisia crispa roots exhibit anti-arthritic properties mediated via angiogenesis inhibition in vitro

机译:生物活性分数和Ardisia Crispa Roots的化合物表现出通过体外血管生成抑制介导的抗关节炎特性

获取原文
           

摘要

Ardisia crispa (Thunb.) A.DC (Primulaceae), is a medicinal herb traditionally used by Asian people as remedies to cure inflammatory related diseases, including rheumatism. The plant roots possess various pharmacological activities including antipyretic, anti-inflammation and antitumor. Previous phytochemical studies of the plant roots have identified long chain alkyl-1,4-benzoquinones as major constituents, together with other phytochemicals. Hexane fraction of the plant roots (ACRH), was previously reported with anti-angiogenic and anti-arthritic properties, while its effect on their anti-arthritic in vitro, is yet unrevealed. Considering the significance of angiogenesis inhibition in developing new anti-arthritic agent, thus we investigated the anti-arthritic potential of Ardisia crispa roots by suppressing angiogenesis, in vitro. Ardisia crispa roots hexane extract (ACRH) was prepared from the plant roots using absolute n-hexane. ACRH was fractionated into quinone-rich fraction (QRF) and further isolated to yield benzoquinonoid compound (BQ), respectively. In vitro experiments using VEGF-induced human umbilical vein endothelial cells (HUVECs) and IL-1β-induced human fibroblast-like synoviocytes for rheumatoid arthritis (HFLS-RA) were performed to evaluate the effects of these samples on VEGF-induced HUVECs proliferation and tube formation, and towards IL-1β-induced HFLS-RA proliferation, invasion, and apoptosis, respectively. Therapeutic concentrations (0.05, 0.5, and 5?μg/mL) tested in this study were predetermined based on the IC50 values obtained from the MTT assay. ACRH, QRF, and BQ exerted concentration-independent antiproliferative effects on VEGF-induced HUVECs and IL-1β-induced HFLS-RA, with IC50 values at 1.09?±?0.18, 3.85?±?0.26, and 1.34?±?0.16?μg/mL in HUVECs; and 3.60?±?1.38, 4.47?±?0.34, and 1.09?±?0.09?μg/mL in HFLS-RA, respectively. Anti-angiogenic properties of these samples were verified via significant inhibition on VEGF-induced HUVECs tube formation, in a concentration-independent manner. The invasiveness of IL-1β-induced HFLS-RA was also significantly inhibited in a concentration-independent manner by all samples. ACRH and BQ, but not QRF, significantly enhanced the apoptosis of IL-1β-induced HFLS-RA elicited at their highest concentration (5?μg/mL) (P??0.05). These findings highlight the bioactive fractions and compound from Ardisia crispa roots as potential anti-arthritic agents by inhibiting both HUVECs and HFLS-RA’s cellular functions in?vitro, possibly mediated via their anti-angiogenic effects.
机译:Ardisia Crispa(Thunb)A.dc(Primulaceae),是一种传统上由亚洲人使用的药草,作为治疗炎症相关疾病,包括风湿病的疗法。植物根部具有各种药理学活动,包括解热,抗炎和抗肿瘤。植物根部的先前植物化学研究已经将长链烷基-1,4-苯醌鉴定为主要成分,以及其他植物化学物质。先前报道了植物根部(ACRH)的己烷级分,抗血管生成和抗关节炎特性,而其对其对体外的抗关节炎的影响尚未迷亡。考虑到血管生成抑制在新型抗关节炎药中的重要性,因此我们通过抑制血管生成,体外抑制血管生成来研究抗关关节炎潜力。使用绝对的正己烷从植物根制备Ardisia Crispa Roots己烷提取物(ACRH)。 acrah分离成富醌的馏分(QRF),进一步分离分离,得到苯并醌类化合物(BQ)。使用VEGF诱导的人脐静脉内皮细胞(HUVECS)和IL-1β诱导的人成纤维细胞样Synociocytes进行类风湿性关节炎(HFLS-RA)的体外实验进行,以评估这些样品对VEGF诱导的HUVECS增殖的影响管形成,并分别朝向IL-1β诱导的HFLS-RA增殖,侵袭和凋亡。在该研究中测试的治疗浓度(0.05,0.5和5μg/ mL)基于从MTT测定获得的IC 50值预先确定。 ACRH,QRF和BQ对VEGF诱导的HUVECS和IL-1β诱导的HFLS-RA施加浓度无关的抗增殖作用,IC50值为1.09≤0.18,3.85?±0.26和1.34?0.16? Huvecs中μg/ ml;和3.60?±1.38,4.47?±0.34和1.09?±0.09?0.09?μg/ ml,分别在HFLS-ra中。通过对VEGF诱导的HUVECS管形成的显着抑制来验证这些样品的抗血管生成性能,以浓度无关。所有样品也以浓度无关的方式显着抑制IL-1β诱导的HFLS-RA的侵袭性。 acraH和BQ,但不是QRF,显着增强了IL-1β诱导的HFLS-Ra的凋亡,以其最高浓度(5?μg/ ml)(p≤≤0.05)。这些发现通过抑制Huvecs和HFLS-RA的细胞功能,突出了来自Ardisia Crispa Roots的生物活性分数和化合物,通过其抗血管生成效应可能介导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号